The EU Commission has approved the use of Merck's drug KEYTRUDA® (pembrolizumab) in combination with chemotherapy as a first treatment.

Encouraging initial human trial Phase 1B results for VRON-0200, an innovative checkpoint modifier for Chronic Hepatitis B, were showcased as a late-breaking entry at the APASL 2024 Global Liver Conference.

Biond Biologics reveals at the 2024 AACR Annual Meeting, the introduction of their pioneering anti-ILT3 antibody, BND-35, designed to transform the tumor microenvironment.

REGENXBIO Reveals Study in The Lancet on Initial Trial for Single-Dose Gene Therapy ABBV-RGX-314 Targeting Wet Age-Related Macular Degeneration.

Neurocrine Biosciences Launches Early-Stage Trial for New VMAT2 Blocker, NBI-1065890, in Adult Participants.

Gilead and Xilio have entered into a unique licensing deal dedicated to the development of an oncology-targeted IL-12 initiative.

Ironwood Pharma Reveals Encouraging Outcomes in Phase 2 STARGAZE Study for Apraglutide Treating GI aGVHD Unresponsive to Steroids.

Avalo secures IL-1β monoclonal antibody and reveals plans for a private investment round potentially reaching $185M.

Akebia Therapeutics Granted US Regulatory Clearance for Vafseo (vadadustat) Pills, a New Therapy for Adult Anemia Linked to Long-term Renal Failure in Dialysis Patients.

Viking Therapeutics Reports Outcomes of Initial Human Study for Oral Pill Version of Combined GLP-1/GIP Agonist VK2735.

TiumBio Lodges Application for Phase 1b Study of Prolonged-Effect Factor VII Agent TU7710 in Subjects with Hemophilia A/B.

First Subject Receives Initial Treatment in Innovent's Phase III Trial (Neoshot) Evaluating IBI310 (Anti-CTLA-4) with Sintilimab in Pre-Surgery Treatment for High Microsatellite Instability/Mismatch Repair Deficient Colon Cancer.